Beam Therapeutics (BEAM) Operating Expenses (2019 - 2026)

Beam Therapeutics (BEAM) has reported Operating Expenses for 8 consecutive years, with $139.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 9.62% year-over-year to $139.0 million; the TTM figure through Mar 2026 stood at $795.7 million (up 210.11% YoY), while the FY2025 annual figure was $523.4 million, up 2998.17% from the prior year.
• Operating Expenses retreated to $139.0 million in Q1 2026 per BEAM's latest filing, from $516.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $516.1 million in Q4 2025 and bottomed at -$324.0 million in Q4 2023.
• Historically, Operating Expenses has averaged $67.0 million across 5 years, with a median of $107.1 million in 2022.
• Annual changes were most pronounced in 2022 — Operating Expenses slumped 323.86% — and 2025, when it soared 7889.81%.
• Beam Therapeutics' Operating Expenses stood at -$256.4 million in 2022, then decreased by 26.36% to -$324.0 million in 2023, then surged by 101.99% to $6.5 million in 2024, then jumped by 7889.81% to $516.1 million in 2025, then tumbled by 73.08% to $139.0 million in 2026.
• Business Quant data shows BEAM's Operating Expenses at $139.0 million in Q1 2026, $516.1 million in Q4 2025, and $12.0 million in Q3 2025.